NCT03559049View on ClinicalTrials.gov

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2028

Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

200mg IV every 21 days

DRUG

Pemetrexed

500mg/m\^2 IV every 21 days

DRUG

Carboplatin

AUC 5 IV every 21 days

DRUG

Rucaparib

600mg PO, BID days 1-21 of each 21 day cycle

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

48109

The University of Michigan Rogel Cancer Center, Ann Arbor

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Clovis Oncology, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER